CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
A Single Arm, Phase II Study of Simvastatin Plus XELOX and Bevacizumab as First-Line Chemotherapy in Metastatic Colorectal Cancer Patients
Youjin Kim, Tae Won Kim, Sae Won Han, Joong Bae Ahn, Seung Tae Kim, Jeeyun Lee, Joon Oh Park, Young Suk Park, Ho Yeong Lim, Won Ki Kang
Cancer Research and Treatment. 2019;51(3):1128-1134.   Published online 2018 November 21    DOI: https://doi.org/10.4143/crt.2018.379

Excel Download

A Single Arm, Phase II Study of Simvastatin Plus XELOX and Bevacizumab as First-Line Chemotherapy in Metastatic Colorectal Cancer Patients
Youjin Kim, Tae Won Kim, Sae Won Han, Joong Bae Ahn, Seung Tae Kim, Jeeyun Lee, Joon Oh Park, Young Suk Park, Ho Yeong Lim, Won Ki Kang
Cancer Research and Treatment. 2019;51(3):1128-1134   Crossref logo
Link1 Link2 Link3
Commentary on a Phase III Trial of Bevacizumab plus XELOX or FOLFOX4 for First-Line Treatment of Metastatic Colorectal Cancer: The NO16966 Trial
Preeta Tyagi, Axel Grothey
Clinical Colorectal Cancer. 2006;6(4):261-264   Crossref logo
Link1 Link2
Continuing Single-Agent Bevacizumab as Maintenance Therapy After Induction XELOX (or FOLFOX) Plus Bevacizumab in First-Line Treatment of Metastatic Colorectal Cancer
Eduardo Díaz-Rubio, Filippo Pietrantonio, Filippo Braud
The Oncologist. 2012;17(11):1426-1428   Crossref logo
Link1 Link2 Link3 Link4
P-0239 Capecitabine and Oxaliplatin (XELOX) Combination Chemotherapy as First-Line Treatment for Metastatic Colorectal Cancer- A Phase II Study
Hesham Tawfik, HananGamal El-Deen
Annals of Oncology. 2012;23:iv98   Crossref logo
Link1 Link2
Prognostic factors of metastatic colorectal cancer patients undergoing first-line chemotherapy plus bevacizumab
A. Bousahba, Z. Behourah
Annals of Oncology. 2019;30:iv56   Crossref logo
Link1 Link2 Link3
Chronomodulated administration of oxaliplatin plus capecitabine (XELOX) as first line chemotherapy in advanced colorectal cancer patients: phase II study
Daniele Santini, Bruno Vincenzi, Gaia Schiavon, Marisa Di Seri, Vladimir Virzí, Bruno Spalletta, Marco Caricato, Roberto Coppola, Giuseppe Tonini
Cancer Chemotherapy and Pharmacology. 2006;59(5):613-620   Crossref logo
Link1 Link2 Link3
Efficacy and tolerance of XELOX plus bevacizumab as first line therapy in Moroccan patients with metastatic colorectal cancer
Tarik Mahfoud, Mohamed Réda Khmamouche, Rachid Tanz, Hassan Errihani, Mohamed Ichou
Annals of Oncology. 2017;28:iii62   Crossref logo
Link1 Link2 Link3
703 PUBLICATION Phase II multicenter study of capecitabine plus oxaliplatin (XELOX) sequentially followed by capecitabine and irinotecan (XELIRI) in first-line therapy for metastatic colorectal cancer (MCRC)
European Journal of Cancer Supplements. 2005;3(2):199-200   Crossref logo
Link1 Link2
XELOX and bevacizumab followed by single-agent bevacizumab as maintenance therapy as first-line treatment in elderly patients with advanced colorectal cancer: the boxe study
Gerardo Rosati, Antonio Avallone, Giuseppe Aprile, Alfredo Butera, Giorgio Reggiardo, Domenico Bilancia
Cancer Chemotherapy and Pharmacology. 2012;71(1):257-264   Crossref logo
Link1 Link2 Link3
Capecitabine/oxaliplatin (XELOX) versus XELOX plus bevacizumab (XELOX + bev) cost-effectiveness for metastatic colorectal cancer (mCRC) in first line treatment: a Brazilian public hospital analysis
F.M. Peria, A.Q. Ungari, F.N. Dos Santos, T. Lins-Almeida, A.A. Nunes
Annals of Oncology. 2016;27:vi482   Crossref logo
Link1 Link2 Link3
This metadata service is kindly provided by CrossRef from May 29, 2014. Cancer Res Treat has participated in CrossRef Text and Data Mining service since October 29, 2014.